Sandoz Group (OTCMKTS:SDZNY) Trading 0.4% Higher – What’s Next?

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) shares traded up 0.4% on Wednesday . The company traded as high as $80.8099 and last traded at $80.49. Approximately 14,264 shares traded hands during mid-day trading, a decline of 21% from the average session volume of 17,995 shares. The stock had previously closed at $80.17.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. The Goldman Sachs Group raised Sandoz Group to a “strong-buy” rating in a research note on Wednesday, April 1st. Barclays upgraded Sandoz Group from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Finally, Royal Bank Of Canada lowered Sandoz Group from a “moderate buy” rating to a “hold” rating in a report on Monday, March 23rd. Three analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Sandoz Group has an average rating of “Strong Buy”.

Sandoz Group Price Performance

The company has a debt-to-equity ratio of 0.53, a current ratio of 1.18 and a quick ratio of 0.77. The stock’s fifty day simple moving average is $84.60 and its 200-day simple moving average is $81.89.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.